Johnson & Johnson (JNJ): Q1 2026 Earnings Beat Expectations with Raised Guidance
Key Takeaways
- Johnson & Johnson reported Q1 2026 sales of $24.1 billion, up 9.9% year-over-year, beating consensus estimates of $23.6 billion.
- Adjusted EPS came in at $2.70, surpassing expectations of $2.68 and down 2.5% from $2.77 in Q1 2025.
- Innovative Medicine sales rose 11.2% to $15.4 billion, driven by Darzalex and Tremfya, despite Stelara headwinds.
- MedTech sales increased 7.7% to $8.6 billion, supported by growth in Cardiovascular and Orthopaedics.
- Company raised full-year 2026 guidance: reported sales midpoint to $100.8 billion (7.0% growth), adjusted EPS midpoint to $11.55 (7.1% growth).
- Stock dipped modestly post-earnings, reflecting tempered enthusiasm for the guidance raise amid conservative sales outlook.
Earnings Context and Why It Matters
I've been keeping a close eye on Johnson & Johnson (JNJ)'s progress since the Kenvue spinoff, and their Q1 2026 earnings offer a clear view into how the company is navigating its focus on Innovative Medicine and MedTech amid challenges like the Stelara patent cliff. As a healthcare bellwether, JNJ's performance provides signals on broader industry trends in oncology, immunology, and medical devices. Investors rightly pay attention to pipeline momentum, including recent approvals like ICOTYDE for plaque psoriasis and VARIPULSE Pro in Europe. The strong results here reinforce JNJ's status as a dividend aristocrat with 62 years of increases, though margin pressures and biosimilar competition will test its goal of double-digit growth by the end of the decade. In this high-interest-rate environment affecting healthcare spending, these numbers help gauge the company's resilience.
Reported Results
Johnson & Johnson posted solid Q1 2026 results, with worldwide sales reaching $24.1 billion—a 9.9% reported increase (6.4% operational) from $21.9 billion in Q1 2025, coming in ahead of consensus estimates of $23.6 billion. U.S. sales climbed 8.3% to $13.3 billion, while International sales increased 11.9% (3.9% operational) to $10.7 billion.
Innovative Medicine sales came in at $15.4 billion, up 11.2% reported (7.4% operational), propelled by Darzalex (up 22.5% operational) and Tremfya (up 68.3% operational), which more than offset a 920 basis point drag from Stelara and declines in Imbruvica. MedTech sales hit $8.6 billion, up 7.7% (4.6% operational), driven by strength in electrophysiology, Abiomed, and Shockwave in Cardiovascular, along with Trauma in Orthopaedics.
GAAP net earnings declined 52.4% to $5.2 billion, with diluted EPS at $2.14 compared to $4.54, reflecting special items. Adjusted net earnings edged down 1.4% to $6.6 billion, and adjusted diluted EPS was $2.70 (down 2.5%), topping the consensus of $2.68. The company also raised its full-year 2026 guidance: reported sales of $100.3–$101.3 billion (midpoint $100.8 billion, 7.0% growth); adjusted EPS of $11.45–$11.65 (midpoint $11.55, 7.1% growth).
Market Reaction and Investor Sentiment
Even with the earnings beat and guidance raise, JNJ shares fell about 0.5%–1% in premarket and early trading on April 15, 2026. From what I see, this reflects some investor caution around the modest full-year sales midpoint of $100.8 billion—barely above consensus—and the slight year-over-year dip in adjusted EPS for the quarter. Sentiment stays positive on the pipeline's strength, but it's tempered by Stelara's impact and ongoing margin pressures. Analysts have highlighted the robust Innovative Medicine growth, with a few upgrading price targets, while others point to the conservative guidance in the face of macroeconomic headwinds.
Understanding JNJ with Tickeron's AI Screener
In my analysis of JNJ, I turned to Tickeron’s AI Screener, which has become a go-to tool in my process for discovering stocks and ETFs. This AI-powered platform lets me filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals, scanning thousands of stocks and ETFs with customizable criteria like industry, market cap, technical indicators, price patterns, and performance metrics. It uncovers trade ideas, trending stocks, breakout candidates, and opportunities far more efficiently than manual methods. One thing that stands out is how it helped me contextualize JNJ against its peers—worth exploring if you're digging into similar names.
Forward Outlook and Key Factors to Monitor
The raised 2026 guidance from Johnson & Johnson shows confidence in picking up growth pace, with operational sales expected at 5.9%–6.9% (midpoint 6.4%) and adjusted operational EPS growth of 4.7%–6.7% (midpoint 5.7%). The company aims for double-digit growth by the decade's end, supported by a strong pipeline that includes ICOTYDE, TECVAYLI + DARZALEX FASPRO, and TECNIS PureSee IOL.
I'm watching Innovative Medicine momentum closely, especially in Oncology (Darzalex, CARVYKTI) and Immunology (Tremfya helping offset Stelara biosimilars). In MedTech, trends in Cardiovascular (electrophysiology, Shockwave) and Orthopaedics will be key as procedural volumes recover.
Key upcoming catalysts include Q2 earnings in July 2026 and the Enterprise Business Review on December 8, 2026. Keep an eye on cost pressures, R&D spending in neuroscience and M&D (mergers and acquisitions), supply chain issues, and regulatory approvals. Global demand in emerging markets and U.S. pricing reforms could affect margins, while free cash flow generation—about $1.5 billion in Q1—continues to back dividends and buybacks. This is important because it underscores JNJ's ability to sustain shareholder returns amid headwinds.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
JNJ in upward trend: 10-day moving average crossed above 50-day moving average on June 11, 2026
The 10-day moving average for JNJ crossed bullishly above the 50-day moving average on June 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 23, 2026. You may want to consider a long position or call options on JNJ as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for JNJ just turned positive on June 23, 2026. Looking at past instances where JNJ's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
JNJ moved above its 50-day moving average on June 22, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in of 350 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 256 cases where JNJ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for JNJ moved out of overbought territory on June 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
JNJ broke above its upper Bollinger Band on June 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 63, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.859) is normal, around the industry mean (19.568). P/E Ratio (26.801) is within average values for comparable stocks, (26.482). Projected Growth (PEG Ratio) (3.006) is also within normal values, averaging (15.849). Dividend Yield (0.023) settles around the average of (0.031) among similar stocks. P/S Ratio (5.845) is also within normal values, averaging (3.939).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an investment holding company with interests in health care products
Industry PharmaceuticalsMajor
Advertisement